1. Park SH, Kim YJ, Rhee KH, et al. A 30-year trend analysis in the epidemiology of inflammatory bowel disease in the Songpa-Kangdong district of Seoul, Korea in 1986-2015. J Crohns Colitis 2019;13:1410-1417.
2. Mak WY, Zhao M, Ng SC, Burisch J. The epidemiology of inflammatory bowel disease: east meets west. J Gastroenterol Hepatol 2020;35:380-389.
5. Thia KT, Loftus EV Jr, Sandborn WJ, Yang SK. An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol 2008;103:3167-3182.
9. Banerjee R, Pal P, Girish BG, Reddy DN. Risk factors for diagnostic delay in Crohn’s disease and their impact on long-term complications: how do they differ in a tuberculosis endemic region? Aliment Pharmacol Ther 2018;47:1367-1374.
10. Yang SK. Current status and clinical characteristics of inflammatory bowel disease in Korea. Korean J Gastroenterol 2002;40:1-14.
12. Park SH, Yang SK, Lim YS, et al. Clinical courses of chronic hepatitis B virus infection and inflammatory bowel disease in patients with both diseases. Inflamm Bowel Dis 2012;18:2004-2010.
13. Park DI, Hisamatsu T, Chen M, et al. Asian Organization for Crohn’s and Colitis and Asian Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment. J Gastroenterol Hepatol 2018;33:20-29.
14. Hong SN, Kim HJ, Kim KH, Han SJ, Ahn IM, Ahn HS. Risk of incident Mycobacterium tuberculosis infection in patients with inflammatory bowel disease: a nationwide population-based study in South Korea. Aliment Pharmacol Ther 2017;45:253-263.
15. Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol 2010;20:202-213.
16. Park SH, Yang SK, Hong SM, et al. Severe disease activity and cytomegalovirus colitis are predictive of a nonresponse to infliximab in patients with ulcerative colitis. Dig Dis Sci 2013;58:3592-3599.
21. Park SH, Hwang SW, Kwak MS, et al. Long-term outcomes of infliximab treatment in 582 Korean patients with Crohn’s disease: a hospital-based cohort study. Dig Dis Sci 2016;61:2060-2067.
22. Seo H, Chang K, Lee SH, et al. Long-term outcomes of infliximab treatment and predictors of response in 195 patients with ulcerative colitis: a hospital-based cohort study from Korea. Scand J Gastroenterol 2017;52:857-863.
23. Seo H, Ye BD, Song EM, et al. Long-term outcomes of adalimumab treatment in 254 patients with Crohn’s disease: a hospital-based cohort study from Korea. Dig Dis Sci 2017;62:2882-2893.
30. Cha JM, Park SH, Rhee KH, et al. Long-term prognosis of ulcerative colitis and its temporal changes between 1986 and 2015 in a population-based cohort in the Songpa-Kangdong district of Seoul, Korea. Gut 2020;69:1432-1440.
31. Ng SC, Zeng Z, Niewiadomski O, et al. Early course of inflammatory bowel disease in a population-based inception cohort study from 8 countries in Asia and Australia. Gastroenterology 2016;150:86-95.
32. Ng SC, Leung WK, Shi HY, et al. Epidemiology of inflammatory bowel disease from 1981 to 2014: results from a territory-wide population-based registry in Hong Kong. Inflamm Bowel Dis 2016;22:1954-1960.
33. Zhao M, Gönczi L, Lakatos PL, Burisch J. The burden of inflammatory bowel disease in Europe in 2020. J Crohns Colitis 2021;15:1573-1587.
35. Ye BD, Hong SN, Seo SI, et al. Changes in the long-term prognosis of Crohn’s disease between 1986 and 2015: the population-based Songpa-Kangdong inflammatory bowel disease cohort study. Gut Liver 2022;16:216-227.
36. Pandey A, Salazar E, Kong CS, et al. Risk of major abdominal surgery in an Asian population-based Crohn’s disease cohort. Inflamm Bowel Dis 2015;21:2625-2633.
37. So J, Tang W, Leung WK, et al. Cancer risk in 2621 Chinese patients with inflammatory bowel disease: a population-based cohort study. Inflamm Bowel Dis 2017;23:2061-2068.
38. Mak WY, Mak OS, Lee CK, et al. Significant medical and surgical morbidity in perianal Crohn’s disease: results from a territory-wide study. J Crohns Colitis 2018;12:1392-1398.
39. Song EM, Lee HS, Kim YJ, et al. Incidence and outcomes of perianal disease in an Asian population with Crohn’s disease: a nationwide population-based study. Dig Dis Sci 2020;65:1189-1196.
40. Wang LH, Yang YJ, Cheng WC, Wang WM, Lin SH, Shieh CC. Higher risk for hematological malignancies in inflammatory bowel disease: a nationwide population-based study in Taiwan. Am J Gastroenterol 2016;111:1313-1319.
41. Jung YS, Han M, Park S, Kim WH, Cheon JH. Cancer risk in the early stages of inflammatory bowel disease in Korean patients: a nationwide population-based study. J Crohns Colitis 2017;11:954-962.
44. Torres J, Billioud V, Sachar DB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis as a progressive disease: the forgotten evidence. Inflamm Bowel Dis 2012;18:1356-1363.
45. Lakatos L, Kiss LS, David G, et al. Incidence, disease phenotype at diagnosis, and early disease course in inflammatory bowel diseases in Western Hungary, 2002-2006. Inflamm Bowel Dis 2011;17:2558-2565.
46. Burisch J, Katsanos KH, Christodoulou DK, et al. Natural disease course of ulcerative colitis during the first five years of follow-up in a European population-based inception cohort: an Epi-IBD study. J Crohns Colitis 2019;13:198-208.
48. Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol 2009;44:431-440.
50. Eriksson C, Cao Y, Rundquist S, et al. Changes in medical management and colectomy rates: a population-based cohort study on the epidemiology and natural history of ulcerative colitis in Örebro, Sweden, 1963-2010. Aliment Pharmacol Ther 2017;46:748-757.
51. Burisch J, Kiudelis G, Kupcinskas L, et al. Natural disease course of Crohn’s disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study. Gut 2019;68:423-433.
52. Lo B, Vester-Andersen MK, Vind I, et al. Changes in disease behaviour and location in patients with Crohn’s disease after seven years of follow-up: a Danish population-based inception cohort. J Crohns Colitis 2018;12:265-272.
54. Jeuring SF, van den Heuvel TR, Zeegers MP, et al. Epidemiology and long-term outcome of inflammatory bowel disease diagnosed at elderly age-an increasing distinct entity? Inflamm Bowel Dis 2016;22:1425-1434.
56. Ramadas AV, Gunesh S, Thomas GA, Williams GT, Hawthorne AB. Natural history of Crohn’s disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates. Gut 2010;59:1200-1206.
57. Zhulina Y, Udumyan R, Henriksson I, Tysk C, Montgomery S, Halfvarson J. Temporal trends in non-stricturing and non-penetrating behaviour at diagnosis of Crohn’s disease in Örebro, Sweden: a population-based retrospective study. J Crohns Colitis 2014;8:1653-1660.
59. Schwartz DA, Loftus EV Jr, Tremaine WJ, et al. The natural history of fistulizing Crohn’s disease in Olmsted County, Minnesota. Gastroenterology 2002;122:875-880.
63. Sjöberg D, Holmström T, Larsson M, et al. Incidence and clinical course of Crohn’s disease during the first year: results from the IBD Cohort of the Uppsala Region (ICURE) of Sweden 2005-2009. J Crohns Colitis 2014;8:215-222.
64. van den Heuvel T, Jeuring S, Zeegers MP, et al. A 20-year temporal change analysis in incidence, presenting phenotype and mortality, in the Dutch IBDSL Cohort: can diagnostic factors explain the increase in IBD incidence? J Crohns Colitis 2017;11:1169-1179.
65. Jeuring SF, van den Heuvel TR, Liu LY, et al. Improvements in the long-term outcome of Crohn’s disease over the past two decades and the relation to changes in medical management: results from the population-based IBDSL cohort. Am J Gastroenterol 2017;112:325-336.
66. Lakatos PL, Golovics PA, David G, et al. Has there been a change in the natural history of Crohn’s disease? Surgical rates and medical management in a population-based inception cohort from Western Hungary between 1977-2009. Am J Gastroenterol 2012;107:579-588.
67. Göttgens KW, Jeuring SF, Sturkenboom R, et al. Time trends in the epidemiology and outcome of perianal fistulizing Crohn’s disease in a population-based cohort. Eur J Gastroenterol Hepatol 2017;29:595-601.
71. Ingle SB, Loftus EV, Harmsen SW, et al. Hospitalization rates for Crohn’s disease patients in Olmsted county, Minnesota, in the pre-biologic era. Am J Gastroenterol 2007;102:S487.
72. Rahman A, Jairath V, Feagan BG, et al. Declining hospitalisation and surgical intervention rates in patients with Crohn’s disease: a population-based cohort. Aliment Pharmacol Ther 2019;50:1086-1093.
73. Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol 2012;10:639-645.
74. Winther KV, Jess T, Langholz E, Munkholm P, Binder V. Longterm risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol 2004;2:1088-1095.
75. Lakatos L, Mester G, Erdelyi Z, et al. Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: results of a population-based study. Inflamm Bowel Dis 2006;12:205-211.
76. Söderlund S, Brandt L, Lapidus A, et al. Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease. Gastroenterology 2009;136:1561-1567.
77. Jess T, Simonsen J, Jørgensen KT, Pedersen BV, Nielsen NM, Frisch M. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology 2012;143:375-381.
79. Lee HS, Park SH, Yang SK, et al. The risk of colorectal cancer in inflammatory bowel disease: a hospital-based cohort study from Korea. Scand J Gastroenterol 2015;50:188-196.
80. Kishikawa J, Hata K, Kazama S, et al. Results of a 36-year surveillance program for ulcerative colitis-associated neoplasia in the Japanese population. Dig Endosc 2018;30:236-244.
81. Gong W, Lv N, Wang B, et al. Risk of ulcerative colitis-associated colorectal cancer in China: a multi-center retrospective study. Dig Dis Sci 2012;57:503-507.
82. Wei SC, Shieh MJ, Chang MC, Chang YT, Wang CY, Wong JM. Long-term follow-up of ulcerative colitis in Taiwan. J Chin Med Assoc 2012;75:151-155.
83. Jess T, Gamborg M, Matzen P, Munkholm P, Sørensen TI. Increased risk of intestinal cancer in Crohn’s disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol 2005;100:2724-2729.
84. Mizushima T, Ohno Y, Nakajima K, et al. Malignancy in Crohn’s disease: incidence and clinical characteristics in Japan. Digestion 2010;81:265-270.
85. Yano Y, Matsui T, Hirai F, et al. Cancer risk in Japanese Crohn’s disease patients: investigation of the standardized incidence ratio. J Gastroenterol Hepatol 2013;28:1300-1305.
86. Lutgens MW, van Oijen MG, van der Heijden GJ, Vleggaar FP, Siersema PD, Oldenburg B. Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis 2013;19:789-799.
87. Zeng Z, Zhu Z, Yang Y, et al. Incidence and clinical characteristics of inflammatory bowel disease in a developed region of Guangdong Province, China: a prospective population-based study. J Gastroenterol Hepatol 2013;28:1148-1153.
89. Hovde Ø, Småstuen MC, Høivik ML, et al. Mortality and causes of death in ulcerative colitis: results from 20 years of follow-up in the IBSEN study. Inflamm Bowel Dis 2016;22:141-145.
90. Romberg-Camps M, Kuiper E, Schouten L, et al. Mortality in inflammatory bowel disease in the Netherlands 1991-2002: results of a population-based study. The IBD South-Limburg cohort. Inflamm Bowel Dis 2010;16:1397-1410.
91. Manninen P, Karvonen AL, Huhtala H, et al. Mortality in ulcerative colitis and Crohn’s disease: a population-based study in Finland. J Crohns Colitis 2012;6:524-528.
92. Caini S, Bagnoli S, Palli D, et al. Total and cancer mortality in a cohort of ulcerative colitis and Crohn’s disease patients: the Florence inflammatory bowel disease study, 1978-2010. Dig Liver Dis 2016;48:1162-1167.
93. Jess T, Frisch M, Simonsen J. Trends in overall and cause-specific mortality among patients with inflammatory bowel disease from 1982 to 2010. Clin Gastroenterol Hepatol 2013;11:43-48.
94. Bitton A, Vutcovici M, Sewitch M, Suissa S, Brassard P. Mortality trends in Crohn’s disease and ulcerative colitis: a population-based study in Québec, Canada. Inflamm Bowel Dis 2016;22:416-423.
96. Jess T, Gamborg M, Munkholm P, Sørensen TI. Overall and cause-specific mortality in ulcerative colitis: meta-analysis of population-based inception cohort studies. Am J Gastroenterol 2007;102:609-617.
97. Duricova D, Pedersen N, Elkjaer M, Gamborg M, Munkholm P, Jess T. Overall and cause-specific mortality in Crohn’s disease: a meta-analysis of population-based studies. Inflamm Bowel Dis 2010;16:347-353.